FDA PMA FDA Class 3 Approved 🇺🇸 United States

Cochlear Implant With Combined Electrical Stimulation And Acoustic Amplification

PMA: P000025 · Supplement: S084 · Decision Sep 15, 2016
Classifications
1
FEI Numbers
11
Registration Numbers
11

Basic Information

Device Name
Cochlear Implant With Combined Electrical Stimulation And Acoustic Amplification
Trade Name
MED-EL COCHLEAR IMPLANT SYSTEM
PMA Number
P000025
Supplement Number
S084
Device Class
FDA Class 3
Product Code
PGQ
Generic Name
Cochlear implant with combined electrical stimulation and acoustic amplification
Medical Specialty
Unknown
Advisory Committee
Ear, Nose, Throat
Decision
Approved
Decision Code
APPR
Decision Date
September 15, 2016
Date Received
December 23, 2015
Supplement Type
Panel Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N
Docket Number
16M-2974

Advisory Committee Statement

Approval for expanding the indications to include the Electro-acoustic Stimulation (EAS) system that is intended to provide electrical stimulation to the mid- to high-frequency region of the cochlea and acoustic amplification to the low-frequency regions, for candidates with residual low frequency hearing sensitivity. The MED-EL EAS System is indicated for partially deaf individuals aged 18 years and older who have residual hearing sensitivity in the low frequencies sloping to a severe/profound sensorineural hearing loss in the mid to high frequencies, and who obtain minimal benefit from conventional acoustic amplification. Typical preoperative hearing of candidates ranges from normal hearing to moderate sensorineural hearing loss in the low frequencies (thresholds no poorer than 65 dB HL up to and including 500 Hz) with severe to profound mid- to high-frequency hearing loss (no better than 70 dB HL at 2000 Hz and above) in the ear to be implanted. For the non-implanted ear, thresholds may be worse than the criteria for the implanted ear, but may not be better. The CNC word recognition score in quiet in the best-aided condition will be 60% or less, in the ear to be implanted and in the contralateral ear. Prospective candidates should go through a suitable hearing aid trial, unless already appropriately fit with hearing aids.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
PGQ Cochlear Implant With Combined Electrical Stimulation And Acoustic Amplification